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Bluetongue virus (BTV) is a non-enveloped dsRNA virus that causes a haemorrhagic disease mainly in sheep. It is an
economically important Orbivirus of the Reoviridae family. In order to estimate the importance of T cell responses
during BTV infection, it is essential to identify the epitopes targeted by the immune system. In the present work, we
selected potential T cell epitopes (3 MHC-class II-binding and 8 MHC-class I binding peptides) for the C57BL/6
mouse strain from the BTV-8 non-structural protein NS1, using H2b-binding predictive algorithms. Peptide binding
assays confirmed all MHC-class I predicted peptides bound MHC-class I molecules. The immunogenicity of these 11
predicted peptides was then determined using splenocytes from BTV-8-inoculated C57BL/6 mice. Four MHC-class I
binding peptides elicited specific IFN-γ production and generated cytotoxic T lymphocytes (CTL) in BTV-8 infected
mice. CTL specific for 2 of these peptides were also able to recognise target cells infected with different BTV
serotypes. Similarly, using a combination of IFN-γ ELISPOT, intracellular cytokine staining and proliferation assays,
two MHC-class II peptides were identified as CD4+ T cell epitopes in BTV-8 infected mice. Importantly, two peptides
were also consistently immunogenic in sheep infected with BTV-8 using IFN-γ ELISPOT assays. Both of these
peptides stimulated CD4+ T cells that cross-reacted with other BTV serotypes. The characterisation of these T cell
epitopes can help develop vaccines protecting against a broad spectrum of BTV serotypes and differentiate infected
from vaccinated animals.Introduction
Bluetongue virus (BTV) is the prototype member of the
Orbivirus genus of the Reoviridae family, transmitted to
the vertebrate host by biting midges [1]. The genome
consists of ten double-stranded RNA segments, encod-
ing 7 structural- and 4 non-structural- proteins [2,3].
The outer capsid layer includes VP2 and VP5 [4,5] re-
sponsible for eliciting serotype-specific neutralising anti-
bodies [6,7]. The non-structural (NS) proteins are
involved in the control of BTV replication, maturation
and export from the cell [8,9].
A long-lasting immunity is developed in animals that re-
cover from bluetongue where both neutralising antibodies* Correspondence: sevilla@inia.es
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unless otherwise stated.[10] and cytotoxic T lymphocytes (CTL) [11,12] are in-
volved in this protective immunity. However, the variability
of the outer capsid of this virus represents one of the major
challenges for the development of a vaccine capable of pro-
tecting animals against multiple serotypes. On the other
hand, cellular immunity plays a key role in BTV immunity
as adoptive transfer of lymphocytes could partially protect
monozygotic sheep from subsequent BTV challenge [13]
and protection can exist in the absence of neutralising anti-
bodies [14,15]. Importantly, the determinants for cellular
immunity are more likely to be shared among serotypes. In-
deed, BTV vaccination and infection in sheep induces CTLs
cross-reactive to multiple serotypes [11,16-18]. Based on
this observation, vaccination designed to elicit T cell re-
sponses can potentially protect animals against several BTV
serotypes.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Rojas et al. Veterinary Research 2014, 45:30 Page 2 of 12
http://www.veterinaryresearch.org/content/45/1/30Analysis of CTL responses to BTV in experimentally
infected sheep showed that virtually all animals recog-
nise epitopes within the non-structural protein 1 (NS1)
[11]. Thus, we have investigated T cell epitopes from the
NS1 protein capable of cross-reacting with multiple
BTV serotypes both in sheep and mouse, as murine
models of BTV infection represent a valuable tool for
designing novel vaccination strategies [19,20]. In the
present report we identify novel CD4+ and CD8+ T cell
epitopes in mouse model from the NS1 protein of BTV-8,
as well as two immunoreactive CD4 epitopes in BTV-8
infected sheep capable of cross-reacting with other
serotypes. This work underlines the potential of stimulat-
ing anti-BTV T cells in order to develop more effective
vaccinations.
Material and methods
Cell lines, virus stock preparation and inactivation
BTV stocks and virus titres were prepared as described pre-
viously [21]. Briefly, Baby Hamster Kidney (BHK) cells were
infected with BTV at multiplicity of infection of 1 and cul-
ture supernatants were collected after 48 h. After 3 cycles
of freeze/thaw and a 2-min sonication step, the superna-
tants were clarified by centrifugation and stored at −80 °C
until use. Virus titres were determined using a standard
plaque titration assay using the Vero cell line. Inactivated
virus (BEI-BTV) were obtained by incubating viral stocks
(1 × 106 plaque forming unit (pfu)/mL) for 48 h at 37 °C
with 3 mM of freshly prepared binary ethyleneimine (BEI)
and neutralised with 0.02 M sodium thiosulphate at the
end of the incubation time.
Infections and animals
Female (7–12 week-old) C57BL/6 mice (Harlan Interfauna
Ibérica, Barcelona, Spain) were inoculated subcutaneously
with 100 pfu of BTV-8 (Belgium/06) three times at 10 days
intervals and sacrificed three days after the last inocula-
tion. Three month-old female sheep (Mallorquina breed)
(n = 8) were inoculated three times at 28-day intervals
with 1 × 105 pfu BTV-8. Venous blood was collected
14 days after the last inoculation and peripheral blood
leukocytes (PBL) were prepared as described below. All
the procedures herein described were carried out under
European Community guidelines and approved by the
local ethical review committee.
Peptides and peptide binding assays
Peptide binding assays to Db and Kb molecules were per-
formed as previously described [21]. Putative binding pep-
tides for Db/Kb/I-Ab molecules from the NS1 protein of
BTV-8 were selected using a combination of predictive al-
gorithms available on the web [22-25] (Table 1). Peptides
were purchased from Altabiosciences (Birmingham, UK) or
Thermo Fisher Scientific (Ulm, Germany). The gp(33–41)peptide (KAVYNFATC) from lymphocytic choriomeningitis
virus (LCMV) known to bind Db and Kb molecules was
used as irrelevant peptide where mentioned. Assays were
performed at least 3 times and binding affinity was ranked
according to peptide gp(33–41). All peptides were dissolved
in DMSO and controls with equivalent amounts of DMSO
were included in all experiments.
Splenocytes and lymph node cells preparation
Spleen and mesenteric lymph nodes were collected from
inoculated mice three days after the last inoculation. Single
cell suspensions were prepared by mechanical disruption of
the organs through a cell strainer. After lysing the erythro-
cytes, splenocytes or lymph node cells from each mouse
were tested against the appropriate stimuli individually at
least in triplicate in T cell medium (RPMI supplemented
with 10%FCS (Lonza Biowhittaker, NJ, USA), 4 mM L-glu-
tamine, 10 mM HEPES, 1% 100X non-essential amino-
acids, 1 mM sodium pyruvate, 100U/mL penicillin/100 μg/
mL streptomycin and 50nM β-mercaptoethanol (all from
Gibco, Invitrogen)).
PBL preparation and in vitro stimulation
PBL were prepared by standard centrifugation method.
Briefly, venous blood collected in EDTA (6 mM final con-
centration) was diluted 1:1 in PBS + 0.03% (w/v) EDTA
(pH 7.4) and overlayed over a Ficoll cushion (GE Health-
care Europe GmbH, Barcelona, Spain). Blood was centri-
fuged at 800 × g for 30 min at room temperature without
brake, and the PBL present at the interface were transferred
to a fresh tube and washed with PBS + 0.03% (w/v) EDTA.
Contaminant erythrocytes were lysed and after two further
washes, cells were cryopreserved in 90% FCS + 10% DMSO
until use. Sheep PBL were thawed by slowly diluting the
cryovial content into PBL medium (RPMI + 17% AIM-V
medium + 5% FCS + 4 mM L-Glutamine + 10 mM
HEPES + 1% 100X non-essential amino-acids + 1 mM
sodium pyruvate + 100U/mL penicillin/100 μg/mL
streptomycin + 50 nM β-mercaptoethanol (all from
Gibco, Invitrogen, CA, USA)). Sheep PBL were washed
three times and rested for 1–2 h at room temperature in
PBL medium before use. In some experiments, 5 × 106
sheep PBL per well were restimulated with 10 μg/mL of
NS1 peptide in 24 well plates for 7 days prior to flow
cytometry analysis for intracellular IFN-γ.
ELISPOT assays
Murine IFN-γ ELISPOT assays were performed according
to the manufacturer protocol (Diaclone, France). Briefly,
2 × 105 splenocytes per well were plated in the presence of
10 μg/mL peptide (final concentration) or chemically-
inactivated BTV (BEI-BTV). Ovine IFN-γ ELISPOT assays
were performed using MSIPS4510 plate (Millipore). Mem-
branes were incubated at 4 °C with 5 μg/mL anti-ovine
Table 1 Prediction of H-2b binding peptides from NS1 and binding assays
Predictive algorithm scores
Position Name Sequence Predicted allele binding SYFPEITHI score
(Db/Kb)
NetMHC predicted affinity
nM (Db/Kb)
BIMAS proPred-I score
(Db/Kb)
Binding assay*
(Db/Kb)
14 NS1(14) YANATRTFL Db 16 341 17.892 +
125 NS1(125) SALVNSERV Db 28 10 138.526 +++
152 NS1(152) GQIVNPTFI Db 28 5 1502.928 +++
222 NS1(222) IQLINFLRM Db/Kb 22/17 239/201 226.359/11.000 ++/++
403 NS1(403) NCYTGAEAL Db/Kb 14/11 21953/18590 3.982/6.000 +/−
141 NS1(141) AMPYIYVPI Kb 22 137 19.800 +
166 NS1(166) Cl I IAYYFYNPD Kb 19 30 1.320 +++
235 NS1(235) KHFNRYASM Kb 17 22 40.000 +++
166 NS1(166) Cl II IAYYFYNPDAADDWI I-Ab NA 194.8 NA NA
402 NS1(402) TNCYTGAEALITTAI I-Ab NA 87.3 NA NA
522 NS1(522) KVHFAGFAAPACESG I-Ab NA 59.1 NA NA
NA: Not available.
*Peptides were ranked relative to the binding of the control peptide gp33-41 from LCMV to Db and Kb molecules on RMA-s cells (fluorescence ratio between NS1 peptide and gp33-41 peptide) (Rojas et al. [21]).
+++: strong binder where ratio > 0.9; ++: moderate binder where ratio > 0.7 and < 0.9; +: weak binder where ratio > 0.5 and < 0.7; and -: no binder where ratio < 0.5.
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were plated at a density of 2–3 × 105 cells per well and
incubated with peptide (10 μg/mL), BEI-BTV, PBL medium
as negative control or concanavalin-A (0.5 μg/mL) as
positive control. Membranes were incubated with biotin-
labelled anti-ovine IFN-γ antibody (MT307-biotin, Mabtech,
Sweden) and developed with streptavidin conjugated to
alkaline phosphatase (ExtrAvidin-AP, Sigma, USA). Mem-
branes were revealed using SigmaFAST BCIP/NBT (Sigma).
Proliferation assays and intracellular cytokine staining
Splenocytes or sheep PBL (2–3 × 105 per well) were
cultured in the presence of BEI-BTV or NS1 peptides
(10 μg/mL). For proliferation assay, cells were cultured for
72 h before 3H-Thymidne was added to each well and incu-
bated overnight. Data are presented as stimulation index
(ratio of incorporated 3H-thymidine in test to control cul-
tures) or as average cpm. For intracellular cytokine staining,
splenocytes were stained with anti-mouse CD4-FITC and
anti-mouse CD8α-PcP antibodies (both from BD Pharmin-
gen, CA, USA) whereas sheep PBL were stained with anti-
ovine CD4-FITC and anti-ovine CD8-PE antibodies (both
from Serotec). After permeabilisation, splenocytes were
stained with anti-mouse IFN-γ-PE and anti-mouse TNF-α-
APC (both from BD pharmingen), whereas sheep PBL were
stained with anti-ovine IFN-γ-A647 (Serotec, UK).
Cytotoxicity assays
CTL assay was quantitated by a standard 51Cr-release assay
[21,26]. Target cells (T) (RMA-S or MC57 cells) cells were0
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Figure 1 T cells from BTV-8 inoculated animals recognise antigenic d
were sacrificed and splenocytes were cultured in the presence of inactivate
detected not only to the serotype used for vaccination (BTV-8) but also to
when in presence of BTV serotype 1, 4 and 8. Data presented are represen
sheep were cultured for 5 days in the presence of inactivated BTV from dif
culture. Proliferative response to BTV-4 and BTV-8 but not BTV-1 was detec
PBLs from BTV-8 infected sheep were cultured with inactivated BTV from d
was produced to BTV-8 and BTV-4 but not BTV-1. Data presented are repre
3H-thymidine incorporated in triplicate cultures and IFN-γ ELISPOT assays a
an unpaired Student t test (control vs BTV).pulsed for 1 h in serum-free medium at 37 °C, 5% CO2 with
10 μg/mL of peptide (NS1 or irrelevant gp33-41 peptide),
BEI-BTV (equivalent to 5 × 105 PFU/mL prior to inactiva-
tion) or BHK-mock lysate as negative control. Target cells
(T) were labelled with 50 μCi of Na2
51CrO4 (Hartmann
Analytic, Germany). Effector (E) (splenocytes) and target
cells were cultured in triplicates at different ratios Culture
supernatants were counted using a 1450 MicroBeta Trilux
counter (Perkin-Elmer, Ohio, USA). The specific percentage
lysis was calculated using the following formulae:
Percentage cytotoxicty ¼ Experimental release‐Spontaneous releaseð Þ
Maximumrelease‐Spontaneous releaseð Þ
100
Statistical analysis
Unpaired two-tailed Student’s t-tests were used to ob-
serve difference within the same animal, whereas non-
parametric two-tailed Mann Whitney rank U tests were
used to compare group of values for several animals.
Data handling analyses was performed using Prism 5.0
(GraphPad Software Inc. San Diego, CA, USA).
Results
Infection with BTV-8 induces T cell responses to other
BTV serotypes in mice and sheep
Splenocytes from BTV-8 inoculated mice were cultured in
the presence of inactivated virus. Proliferation (Figure 1A)
and IFN-γ (Figure 1B) were not only detected to inactivated
BTV-8 but also to inactivated BTV-4 in all 5 mice tested0
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C D
eterminants shared by BTV serotypes. C57BL/6 mice inoculated
d BTV from different serotypes. (A) Proliferative responses to BTV were
serotype 1 and 4. (B) Similarly, splenocytes produced IFN-γ specifically
tative of 5 mice inoculated with BTV-8. (C) PBLs from BTV-8 infected
ferent serotypes and tritiated-thymidine was added in the last 16 h of
ted in the cultures. Data presented are representative of 6 sheep. (D)
ifferent serotypes for 48 h and IFN-γ was measured by ELISPOT. IFN-γ
sentative of 3 sheep. Proliferation is presented as the average cpm of
s average number of spots in triplicate cultures. *denotes p < 0.05 using
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perimentally infected with BTV-8, we detected proliferative
responses and IFN-γ production not only to BEI-
inactivated BTV-8 but also to BTV-4. However no prolifer-
ative response or specific IFN-γ production to BTV-1 was
detected (Figures 1C and 1D). It remains unclear whether
this difference in response is due to a different antigen rep-
ertoire presented to the host, or to a mechanism of im-
mune evasion specific to BTV-1. Taken together, these
results confirm that T cells from infected animals can
cross-react with several serotypes.
Prediction of peptide binding from NS1 protein to H-2b
haplotype and binding assays
Using a combination of three epitope prediction algo-
rithms available on the web (SYFPEITHI, Pro-Pred-I,
NetMHC I and II) [22-25], 11 peptides from NS1 pro-
tein from BTV-8 were selected and synthesised (Table 1).
The ability of these synthesised peptides to bind H-2 Db
and Kb molecules was assessed using a binding assay on
RMA-S cells. All 8 peptides predicted to bind murine
MHC class I molecules showed binding affinity for ei-
ther Db or Kb molecules. NS1 peptide binding was
ranked according to the binding to RMA-S cells of the
control peptide gp33-41. Four NS1 peptides displayed a
strong affinity for either Db or Kb molecules, and con-
versely, 3 NS1 peptides only had low affinity for their
MHC molecules (Table 1). Peptide NS1(222) displayed,
as predicted, moderate binding to both Db and Kb mole-
cules. Overall, the NetMHC algorithm appears to predict
more accurately the peptide binding to Db and Kb mole-
cules, although NS1(403) peptide which was not pre-
dicted to bind using this algorithm had weak affinity for
Db in RMA-S cell binding assays. Thus, we can conclude
that the combination of several predictive algorithms
proved useful for the detection of putative T cell
epitopes.
Response to Db and Kb binding NS1 peptides
Splenocytes from BTV-8 inoculated mice were cultured
for 48 h in the presence of NS1 peptides and the specific
IFN-γ production was assessed using ELISPOT assays
(Figure 2A). Only peptide NS1(125) showed a significant
IFN-γ production in 5 out of 6 mice tested, which was
significant using a Mann Whitney rank test comparing
the NS1(125) peptide group to the control group. Pep-
tides NS1(141), NS1(152), NS1(166) I, NS1(222), NS1
(235) and NS1(403) showed significant IFN-γ production
in 3 or 4 mice out of 6 (by student t test), whereas pep-
tide NS1(14) induced specific IFN-γ production in only
1 mouse out of 6 and thereby was not investigated fur-
ther. We then proceeded to generate CTL lines specific
for these NS1 peptides from splenocytes of inoculated
mice. After 5–6 days of in vitro stimulation with NS1peptide, splenocyte cultures were tested for cytotoxicity
by 51chromium release assay against RMA-S cells either
pulsed with the NS1 peptide of interest or gp33-41 pep-
tide as control (Figure 2B). Peptides NS1(125), NS1
(152), NS1(235) and NS1(403) generated CTLs in BTV-
8 inoculated mice, whereas no evidence of specific CTL
activity was detected to NS1(141), NS1(166) I, or NS1
(222) peptides. Taken together, these data suggest that
NS1(125), NS1(152), NS1(235) and NS1(403) peptide are
CTL epitopes from NS1 in the context of H-2b.
To analyse whether these 4 peptides were naturally
processed and presented by target cells cultured with
BTV (Figure 2C). MC57 cells were incubated with BEI-
BTV either from serotype 1, 4 or 8 and used as target
cell for CTL raised against NS1(125), NS1(152), NS1
(235) or NS1(403) peptide. MC57 cells were pulsed with
the relevant NS1 peptide as positive control, or with
mock BHK lysate as negative control. CTLs specific for
NS1(152), NS1(235) or NS1(403) peptide were able to
lyse target cells cultured with BTV-8. However, CTLs
specific for NS1(125) peptide failed to recognise target
cells cultured in the presence of BTV. Importantly,
CTLs specific for NS1(152) or NS1(403) peptide were
capable of lysing target cells pulsed either with BTV-1 or
BTV-4, demonstrating that these CTLs can recognise
cells infected with different BTV serotypes. Therefore,
NS1(152) and NS1(403) peptides are naturally processed
by other BTV serotypes and are capable of inducing
cross-reactive CTL responses.
Response to I-Ab binding peptides
Production of IFN-γ to putative I-Ab binding peptides
from NS1 was measured by ELISPOT assays on spleno-
cytes from BTV-8 inoculated mice (Figure 3A). No pep-
tide displayed consistent production of IFN-γ in these
assays, but peptides NS1(166) II and NS1(522) showed
significant cytokine production (by Student’s t test) in 3
out of 6 mice tested. Proliferation was measured
using 3H-thymidine incorporation in lymph node cells
(Figure 3B) and splenocytes (Figure 3C) from BTV-8
inoculated C57BL/6 mice cultured for 72 h in the presence
of NS1 peptides. Peptide NS1(166) II showed significant
proliferative response in splenocytes (Mann Whitney test)
whereas peptides NS1(402) and NS1(522) did not
displayed significant and consistent proliferative responses
in spleen (Figure 3C). In lymph nodes, peptides NS1(166)
II and NS1(522) showed significant proliferative re-
sponse (Figure 3B). Moreover, intracellular staining
for IFN-γ and TNF-α demonstrated by flow cytometry
that CD4+ T cells responded to NS1(166) II and NS1
(522) peptides, but not to NS1(402) peptide (Figure 3D).
Taken together, these data indicated that NS1(166) II
and NS1(522) peptides are CD4 epitopes from BTV-8
in C57BL/6 mice.
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Figure 2 Response to Db and Kb binding NS1 peptides. (A) Splenocytes were cultured with NS1 peptides for 48 h and IFN-γ production was
measured using ELISPOT assays. Peptides NS1(141/152/166/222/403) showed specific IFN-γ in only 3 or 4 mice out of the 6 mice used in these
experiments. Peptide NS1(14) was only positive in one mouse, whereas peptide NS1(125) was positive for IFN-γ production in 5 out of 6 mice.
(*p < 0.05 Mann–Whitney test NS1(125) vs control). Data are presented as the mean number ± SD of IFN-γ-producing cells in response to stimuli
in 6 mice. (B) CTL lines were generated by in vitro NS1 peptide stimulation (effector: E) and tested against RMA-S cells (target: T) pulsed with the
NS1 peptide used for in vitro stimulation or with the control peptide gp(33). Peptides NS1(125/152/235/403) generated specific CTL responses,
whereas no CTLs were generated using NS1(141/166(I)/222) peptides. Data presented are representative of at least 4 mice for each peptide
(*p < 0.05 unpaired Student t test NS1 peptide vs control gp(33) peptide). (C) CTL lines specific for NS1(125/152/235/or 403) peptide were also
tested against MC57 cells as target (E:T = 50:1) pulsed with relevant NS1 peptide as positive control, mock BHK lysate as negative control, or
BEI-BTV-1, 4 or 8 to assess epitope processing. CTLs specific for NS1(152) and NS1(403), but not NS1(125) peptide, were capable of recognising
target cells pulsed with BTV from different serotypes (p < 0.05 unpaired Student t test: mock lysate vs NS1 peptide, BTV-1, 4 or 8). CTLs specific for
NS1(235) peptide were able to recognise target cells pulsed with BTV-8. However due to the limited number of CTL obtained in these
experiments, we were not able to confirm the expression of this epitope in BTV-1 or 4. All CTL data presented are representative of at least 4 mice
for each peptide. §: not done.
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To determine whether some degree of overlap in these
epitopes is present in BTV-8-infected sheep, we stimu-
lated in vitro PBL from sheep infected experimentally
with BTV-8 with NS1 peptides. After 48 h, the specific
IFN-γ response was assessed using an ELISPOT assay
(Figure 4). Peptides NS1(141) and NS1(522) showed sig-
nificant IFN-γ production in most infected sheep.Peptide NS1(166) II was also immunogenic but to a
lesser extent (in 5 out of 8 sheep tested). Therefore, we
further investigate peptides NS1(141) and NS1(522).
PBL from infected sheep were cultured in the presence
of NS1 peptide, and proliferation was assessed using 3H-
thymidine incorporation at day 5 (Figures 5A and 5B).
Peptide NS1(141) and NS1(522) induced proliferative re-
sponse in 3 out of 4 tested sheep. These data confirmed
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Figure 3 NS1(166) II and NS1(522) peptides are CD4 epitopes in C57BL/6 mice. (A) No consistent significant production of IFN-γ was
detected by ELISPOT to any peptide using a Mann–Whitney test. However, in individual mice significant IFN-γ production (using an unpaired
Student’s t test) was detected in 3 out of 6 BTV-8-inoculated mice to peptides NS1(166) II and NS1(522) and in 2 out of 6 mice to peptide NS1(402).
(B) Lymph node cells from BTV-8 inoculated mice proliferated significantly to both NS1(166) II and NS1(522) peptides. * p < 0.05 Mann–Whitney test
on NS1 peptide vs control. (C) Splenocytes from BTV-8-inoculated mice consistently proliferated to the NS1(166) II peptide, whereas NS1(402) and NS1
(522) peptides showed no specific proliferation. * p < 0.05 Mann–Whitney test on NS1 peptide vs control. (D) Using intracellular cytokine staining, we
observed that IFN-γ and TNF-α were produced by CD4+ T cells when cultured in the presence of NS1(166) II and NS1(522) peptides, but
not with NS1(402) peptide. Dot-plots are representative of at least 3 different mice. Percentages indicate the number of cytokine producing
cells in the CD4+ population.
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Figure 4 Sheep PBL responses to NS1 predicted peptides. PBLs
from sheep infected experimentally with BTV-8 were cultured for
48 h with NS1 peptides and specific IFN-γ response was measured
using an ELISPOT assay. Peptide NS1(141) and NS1(522) showed
specific IFN-γ production in 7 out of 8 sheep. Peptide NS1(166) II
showed specific IFN-γ production in 5 out of 8 sheep. Data are
presented as the mean number ± SD of IFN-γ-producing cells in
response to stimuli in 8 sheep. *p < 0.05 and **p < 0.01 Mann
Whitney test NS1 peptide group vs control.
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in sheep. To determine whether NS1(141) and NS1(522)
peptides elicit CD4+ or CD8+ T cell responses, sheep
PBL were stimulated with peptide and intracellular IFN-
γ was measured by flow cytometry (Figure 5C). For both
peptides, IFN-γ was detected in CD4+ T cells but not in
CD8+ T cells. Thus, these data indicate that NS1(141)
and NS1(522) peptides are CD4 epitopes in sheep.
To establish whether these CD4+ T cells specific for
NS1(141) or NS1(522) peptide can cross-react with sev-
eral BTV serotypes, sheep PBL stimulated with these
peptides were cultured in the presence of BEI-BTV from
different serotypes (Figure 6). In some cases, BEI-BTV
stimulation resulted in IFN-γ production in the CD4
negative compartment to all 3 serotype tested, probably
as a result of antigen recognition by BTV-specific CD8 +T
cells still present in the PBL cultures. This suggests that
CD8 epitopes can also be shared among serotypes in sheep.
Cells specific for both peptides were capable of producing
IFN-γ not only to the serotype used for inoculation
(BTV-8) but also to BTV-1 and BTV-4. Therefore, these
data indicate that NS1(141) and NS1(522) are CD4
epitopes shared among several BTV serotypes.
Discussion
In the present work, we described CTL and T helper epi-
topes from the NS1 protein of BTV-8 in mice and sheep.
Three CTL and 2 helper epitopes were described in
C57BL/6 mice, and 2 helper epitopes were described in
sheep. These T cells are naturally activated during BTV-8infection and are likely to contribute to the elimination of
the virus. As previously described [18], we confirmed that
T cells can cross-react with other BTV serotypes. Interest-
ingly, IFN-γ production to BTV-1 was always lower when
compared to BTV-8 or BTV-4, indicating either that this
strain can interfere with IFN-γ production or that BTV-1
may not share some antigenic determinants responsible for
the IFN-γ production observed with its other two sero-
types. It remains unclear whether the different response to
BTV-1 observed in these experiments was due to a differ-
ent antigen repertoire presented to the host, or to a mech-
anism of immune evasion specific to BTV-1.
Murine models for BTV infection are well estab-
lished [19,27] and represent a very useful tool to de-
sign more rational and cost-effective vaccination
strategies for the disease. The description of T cells
determinants in mice will therefore allow for a better
monitoring of effective vaccination to the virus in
these experimental models. In turn, this is likely to
further improve the design of novel vaccination ap-
proaches in the natural host. Predictive algorithms for
MHC binding peptides have proved useful in identify-
ing T cell epitopes for virus or tumour antigens [28].
In the present work, we have used a combination of
algorithms available on the web to predict H-2b bind-
ing peptides from NS1. The binding to MHC class I
molecules of these predicted peptides was verified
using binding assay with RMA-S cells [21,29]. The
NetMHC algorithm appears to predict more accur-
ately the binding to Db and Kb molecules than the
other 2 algorithms. However, NS1(403) peptide which
was a predicted binder using SYFPEITHI and Pro-
Pred-I algorithms but not by the NetMHC algorithm
showed weak affinity for Db in RMA-S cell binding
assays. Importantly, in spite of its weak binding NS1
(403) peptide was a CTL epitope shared among sev-
eral BTV serotypes. On the other hand, NS1(125)
peptide which showed strong binding to Db could
elicit IFN-γ production but displayed only a weak
CTL activity in inoculated mice, with no evidence of
natural processing in BTV-infected cells. Taken to-
gether these data confirm that MHC binding affinity
alone is not always a good predictor of CTL activity,
and that immune responses may be directed to low
affinity peptides [30].
The immunogenicity of these predicted peptides
was assessed in BTV-8 inoculated mice using a com-
bination of IFN-γ ELISPOT assays, intracellular cyto-
kine staining, CTL assays (for MHC class I binding
peptides) and proliferation assays (for MHC class II
binding peptides). Only NS1(125) peptide displayed
consistent IFN-γ production in all inoculated mice.
However, this peptide only displayed weak CTL activ-
ity and no evidence of natural processing was
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Figure 5 Peptides NS1(141) and NS1(522) are CD4 epitopes in sheep. PBLs from sheep infected experimentally with BTV-8 were cultured for
5 days with (A) NS1(141) or (B) NS1(522) peptides and proliferative responses were measured using 3H-thymidine incorporation. Three out of 4
sheep tested had specific proliferative responses to these peptides. Data are presented as stimulation index representing the ratio of cpm
between peptide stimulated PBLs vs DMSO control culture PBLs. * p < 0.05 Unpaired Student t test NS1 peptide vs control. (C) To determine
whether the proliferative response and IFN-γ production to these NS1 peptide in sheep was mediated by CD4+ or CD8+ T cells, intracellular
IFN-γ staining of peptide-stimulated sheep PBL was performed and data were analysed by flow cytometry. The production of IFN-γ to NS1(141)
and NS1(522) peptides was detected in CD4+ T cells but not in CD8+ T cells. Data presented are representative of 3 sheep.
Rojas et al. Veterinary Research 2014, 45:30 Page 9 of 12
http://www.veterinaryresearch.org/content/45/1/30
Figure 7 Murine and ovine T cell epitopes from NS1 have identical sequence in most BTV serotypes. Sequence identities were searched
using BLASTp. Dashes indicate identical amino-acid residues in BTV-8 and the compared sequence. Where residues differed, the single letter code
for amino-acid residues is used to indicate the difference.
A
B
Figure 6 Peptide NS1(141) and NS1(522) are presented by several BTV serotypes. PBLs from infected sheep were stimulated either with
(A) NS1(141) or (B) NS1(522) peptide. After 1-week expansion, IFN-γ production was assessed against several BTV serotypes. CD4+ T cells specific
for NS1(141) or NS1(522) were able to produce IFN-γ not only in the presence of BTV-8 (used for infection) but also for BTV-1 and −4.
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NS1(235) and NS1(403) induced moderate IFN-γ pro-
duction, however they displayed consistent CTL activ-
ity and were able to lyse target cells pulsed with
BTV. Two CD4 epitopes were also identified in
C57BL/6 inoculated mice using a combination of pro-
liferation assay and intracellular cytokine staining.
These data highlight the importance of using several
complementary techniques to identify novel epitopes.
Importantly, we were able to show that peptides
NS1(152) and NS1(403) could recognised cells pulsed
with different BTV serotypes demonstrating that these
CTL epitopes are presented by other viral serotypes.
In the case of CTL raised against NS1(235) peptide,
we were not able to use target cells pulsed with other
BTV serotypes due to the limited amount of cells ob-
tained in these experiments. Nonetheless, it is very
likely that NS1(235) will also be presented by other
BTV serotypes as its sequence is identical in BTV-1
and BTV-4. Moreover, the sequences from these NS1
epitopes are shared among a wide variety of BTV se-
rotypes (Figure 7). Thereby, vaccination activating T
cells responses to these epitopes is likely to set the
basis for a better protection across BTV serotypes.
We also describe two CD4 epitopes from NS1 in
sheep. Both of these helper epitopes were not only
presented by BTV-8, but also by BTV-1 and BTV-4.
Definition of these cross-reactive epitopes is an essen-
tial part of the ongoing effort to improve BTV vaccin-
ation and monitoring. From a biological point of
view, defining these T cell epitopes will help under-
stand the process of infection of BTV, as well as its
interaction with the host immune system. The suscep-
tibility that BTV displays to type I interferon as well
as the lymphopenia observed in the host after infec-
tion, indicate that BTV is immunosuppressive [31].
Animals that recover from the infection develop a
strong humoral and cellular immunity to the virus,
demonstrating that effective immunity to BTV can be
eventually mounted. However during the infection
period, animals are immune-compromised and there-
fore susceptible to opportunistic infections. A better
understanding of the T cell response to BTV may be
central to comprehend the mechanisms through
which this virus is capable of evading the host im-
mune response and often persist for month in the
host [32].
The characterisation of more T cell determinants
from BTV in breeds used widely in sheep farming is
also important for the monitoring of the health status
of naïve populations to BTV. In addition, this know-
ledge may help understand the susceptibility of these
breeds to BTV outbreaks. Vaccination designed to ac-
tivate T cells specific for determinants shared amongserotypes is also likely to limit the economical impact
that BTV outbreaks can have on naïve populations.
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